FOLH1 and hepatocellular carcinoma: NIR-PIT has been demonstrated to be effective with a variety of different APCs, including anti-CD20 (Nagaya et al., 2016a) for B-cell lymphoma, prostate-specific membrane antigen (PSMA) antibody (Nagaya et al., 2017), antimesothelin antibody (Hanaoka et al., 2015) and glypican-3 targeted human heavy chain antibody for hepatocellular cancer (Nagaya et al., 2016b).